Blood plasma

Global Blood Plasma Market Report 2022 to 2030: Featuring Bayer, Biotest, CSL, Fusion Health and Octa Pharma Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 3, 2022
Biotechnology, Pharmaceutical, Health, Blood plasma, COVID-19, Awareness, Growth, LFB, Element, Infection, Industry, Immunodeficiency, Population, WHO, Antibody, CSL Limited, Revenue, Organization, Bayer, Degenerative disease, PID, Grifols, Patient, Medical device, Agriculture, Pharmaceutical industry, Takeda

The rise in chronic conditions and increasing demand for immunoglobulin drive the development of the industry.

Key Points: 
  • The rise in chronic conditions and increasing demand for immunoglobulin drive the development of the industry.
  • The expansion in the maturing population around the world might trigger a spike in infections that require blood treatment.
  • Market participants such as Biotest, CSL Limited, Grifols, S.A, Kedrion Biopharma, LFB S.A, Octa Pharma, Bayer AG, Sanofi, Fusion Health, and Takeda are some of the key players operating in the market.
  • The publisher has segmented the blood plasma market report based on type, application, end-use, and region:
    Blood Plasma, Type Outlook (Revenue - USD Billion, 2018 - 2030)

Daxor’s Blood Volume (BVA-100®) Diagnostic Demonstrates Clinical Utility In Critically-Ill COVID-19 Patients In Newly Published Data in Journal Critical Care

Retrieved on: 
Wednesday, August 4, 2021
Branches of biology, Anatomy, Medical specialties, Blood, Hematology, Cardiovascular physiology, Blood volume, Transfusion medicine, Intravascular volume status, Blood test, Blood plasma, Capillary

Oak Ridge, TN, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces new data published in the journal Critical Care showing Daxor’s unique BVA-100 diagnostic blood test provides insights into the pathophysiology of volume derangements and capillary distress in critically ill COVID-19 patients enabling improved care.

Key Points: 
  • The Research Letter titled Blood volume and albumin transudation in critically-ill COVID-19 patients studied the abnormal blood volume profiles in mechanically ventilated patients admitted to the ICU at a leading medical center in New York.
  • The data shows that COVID-19 patients suffer from significant capillary damage and blood volume deficits that care teams became aware of through the use of the Daxor BVA-100 blood test.
  • Daxors BVA test is the first and only diagnostic test cleared by FDA that offers insights into patients blood volume with a 98% accurate measure of plasma and red cell volume.
  • We developed and market the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms.

ADMA Biologics to Report Second Quarter 2021 Financial Results on August 11, 2021

Retrieved on: 
Wednesday, August 4, 2021
Life sciences, Anatomy, Biotechnology, Blood, Transfusion medicine, Biopharmaceutical, Pharmaceutical industry, Adma, Boca Raton, Florida, Blood plasma

RAMSEY, N.J. and BOCA RATON, Fla., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (ADMA or the Company), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it will report financial results for the second quarter ended June 30, 2021 on Wednesday, August 11, 2021 after the U.S. financial markets close.

Key Points: 
  • RAMSEY, N.J. and BOCA RATON, Fla., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (ADMA or the Company), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it will report financial results for the second quarter ended June 30, 2021 on Wednesday, August 11, 2021 after the U.S. financial markets close.
  • ADMAs management team will host a live conference call and audio webcast on that date at 4:30 p.m.
  • ET to discuss its financial results and other Company updates.
  • ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida.

ADMA Biologics Announces Successful Completion of FDA Pre-Approval Manufacturing Facility Inspection

Retrieved on: 
Tuesday, July 20, 2021
Life sciences, Biotechnology, Health sciences, Transfusion medicine, Biopharmaceutical, Pharmaceutical industry, Pharmacy, Blood plasma, Adma, Food and Drug Administration

With this favorable inspection outcome, we are anticipating receiving approval for the VanRx in the second half of 2021.

Key Points: 
  • With this favorable inspection outcome, we are anticipating receiving approval for the VanRx in the second half of 2021.
  • Additionally, the expected approval will enable ADMA to onboard third-party fill-finish contracts as a new and accretive revenue source.
  • ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases.
  • ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida.

DGAP-News: Biotest AG: Biotest AG opens 11th plasma collection centre in Hungary

Retrieved on: 
Tuesday, July 20, 2021
Anatomy, Software, Branches of biology, Electromagnetism, Budapest, Plasma, Blood plasma, KDE Plasma 5

Biotest received an operating permit for its 11th plasma collection centre in Hungary from the country's national public health authority OTH.

Key Points: 
  • Biotest received an operating permit for its 11th plasma collection centre in Hungary from the country's national public health authority OTH.
  • Thus, the company is further expanding its plasma collection capacity and is safeguarding the plasma supply to future growth.
  • The first plasma collection centre in Budapest was opened in 2009 by Plazmaszolglat Kft., a 100% subsidiary of Biotest AG.
  • The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.

SomaLogic Customizable Protein Panels With Industry-Leading 7,000-Plex Assay Now Available

Retrieved on: 
Tuesday, July 6, 2021
Health, Biotechnology, Anatomy, Blood, Body fluids, Branches of biology, SomaLogic, Serum, Blood plasma, PLEX

We are excited to be able to give them this flexibility, said SomaLogic Chief Executive Officer Roy Smythe, M.D.

Key Points: 
  • We are excited to be able to give them this flexibility, said SomaLogic Chief Executive Officer Roy Smythe, M.D.
  • SomaLogic is now offering small-plex panels with targeted analytes for specific disease states.
  • These panels include:
    SomaLogics SomaScan Custom Panels are also now available between 1 and 1,500 analytes, offering flexibility to academic and pharma partners.
  • SomaLogic can run 7,000 protein measurements on a single 55 microliter plasma or serum sample.

DGAP-News: Biotest AG: Biotest AG opens fifth plasma collection centre in Czech Republic

Retrieved on: 
Wednesday, June 30, 2021
Anatomy, Software, Branches of biology, Blood, Blood plasma, Hematology, Transfusion medicine, KDE Plasma 5, Preferred stock

Biotest has received the operating license for its fifth plasma collection centre in Czech Republic from the country's national public health authority SUKL.

Key Points: 
  • Biotest has received the operating license for its fifth plasma collection centre in Czech Republic from the country's national public health authority SUKL.
  • The centre is located in the historic centre of the South Bohemian city of Budweis.
  • Biotest is continuing on its planned path to expand its own donation stations in order to increase its plasma collection capacity.
  • The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.

SomaLogic customizable protein panels with industry-leading 7,000-plex assay now available

Retrieved on: 
Tuesday, June 22, 2021
Anatomy, Blood, Body fluids, Branches of biology, SomaLogic, Serum, Blood plasma, PLEX

We are excited to be able to give them this flexibility, said SomaLogic Chief Executive Officer Roy Smythe, M.D.

Key Points: 
  • We are excited to be able to give them this flexibility, said SomaLogic Chief Executive Officer Roy Smythe, M.D.
  • SomaLogic is now offering small-plex panels with targeted analytes for specific disease states.
  • These panels include:
    SomaLogics SomaScan Custom Panels are also now available between 1 and 1,500 analytes, offering flexibility to academic and pharma partners.
  • SomaLogic can run 7,000 protein measurements on a single 55 microliter plasma or serum sample.

ADMA Biologics to Participate in the Raymond James Human Health Innovation Virtual Conference

Retrieved on: 
Monday, June 14, 2021
Life sciences, Biotechnology, Health sciences, Pharmaceutical industry, Biopharmaceutical, Pharmacy, Adma, Food and Drug Administration, Boca Raton, Florida, Blood plasma

RAMSEY, N.J. and BOCA RATON, Fla., June 14, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (the Company), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the Raymond James Human Health Innovation Virtual Conference on June 21, 2021 at 9:20 a.m.

Key Points: 
  • RAMSEY, N.J. and BOCA RATON, Fla., June 14, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (the Company), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the Raymond James Human Health Innovation Virtual Conference on June 21, 2021 at 9:20 a.m.
  • A webcast of the event will be available on the Companys website at https://ir.admabiologics.com/events-webcasts and will be archived for 90 days following the event.
  • ADMA Biologics is an end-to-end American commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases.
  • ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida.

Quanterix’ Simoa Technology Powers Largest and Most Diverse Global Investigation of Plasma Neurofilament Light’s Role in Dementia Diagnosis

Retrieved on: 
Monday, June 7, 2021
Research, Technology, Genetics, Other Technology, Clinical trials, Cardiology, Health, Science, Oncology, Other Science, Anatomy, Branches of biology, Body fluids, Blood, Blood plasma, Hematology, Transfusion medicine, Plasma

However, few studies go as far as this to showcase plasma NfLs many advantages for non-invasive, routine neurodegenerative screenings and diagnostics.

Key Points: 
  • However, few studies go as far as this to showcase plasma NfLs many advantages for non-invasive, routine neurodegenerative screenings and diagnostics.
  • For this study, 2269 total individuals were examined from two independent multicenter cohorts from Kings College London and the Swedish BioFINDER study using the Simoa platform and Quanterix in-house assays.
  • Finally, the study uncovered new evidence to determine and validate age-related concentration cutoffs for plasma NfL across the range of disorders under observation.
  • Findings from the research corroborate the correlation between major neurodegenerative disorders and increased plasma NfL concentrations on an unprecedented scale.